Australia's Universal Biosensors gains on deal to develop cancer device

Universal Biosensors

20/09/2021 06:00

** Shares of Universal Biosensors  UBI.AX  rise as much as
4.7% to A$0.90, their biggest intraday pct gain since Sept 13
    ** Medical diagnostics co enters agreements with Victorian
Cancer Biobank, Spain-based research centre CIC bioGUNE and
CIC's clinical partner in the country, Basurto University
Hospital  urn:newsml:reuters.com:*:nASX5jv5sf
    ** Agreements to start clinical studies for UBI's Tn
Antigen, a cancer biosensor that measures a patient's cancer
status
    ** Earlier this month, UBI signed a deal to supply cancer
patient samples to develop and validate Tn Antigen's performance
 urn:newsml:reuters.com:*:nASX87v9Sb
    ** UBI stock has doubled in value this year, as of last
close
    
  

 (Reporting by Harish Sridharan in Bengaluru)
 ((harish.sridharan@thomsonreuters.com))